Novo Nordisk's Q2 2025 sales surge as Wegovy demand grows, driven by new obesity drug data. Click here to read an analysis of ...
The restructuring marks the first major action authorised by new CEO Mike Doustdar in a bid to turn the company’s fortunes ...
While only two therapies have so far gained approval, the broader pipeline paints a picture of strong research and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback